All News

As rates of merkel cell carcinoma increase, patients should be aware of the risk factors and symptoms of this skin cancer.

The combination may offer patients with recurrent, platinum-agnostic ovarian cancer a more effective, non-platinum-based treatment option.

Keytruda plus gemcitabine and higher doses of radiotherapy showed promising efficacy and safety results in patients with muscle-invasive bladder cancer.

A clinical office practice nurse embraces the positive with her patients and strives for improved outcomes, even when it may not seem possible.

"Although Carolyn loved her role as a navigator, she realized she could help patients with lung cancer with a screening program to help with earlier detection."

The Food and Drug Administration granted a breakthrough therapy designation to a new drug that can be used to treat patients with mantle cell lymphoma.

A woman who underwent surgery for breast cancer shares a transformative experience in which she posed for a photographer who documented her mastectomy scars.

From Ina Jaffe’s breast cancer news to a couple moving up their wedding due to a cancer diagnosis, here’s what’s happening in the cancer landscape this week.

After a 13-year follow-up, researchers found an association between aspirin and ibuprofen use and distal adenoma, recurrent adenoma and colorectal cancer.

A cancer survivor shares tips for getting through dreaded follow-up appointments that may lead to anxiety.

Will patients be given a placebo? Are clinical trials safe? An expert answers these questions and more.

Donald Rumsfeld, who died from multiple myeloma, served as secretary of defense under Presidents Gerald R. Ford and George W. Bush.

A patient wrote about his oncology nurse when receiving chemotherapy, whose personality helped him look forward to his sessions.

The FDA approval provides patients with an alternative therapy to the only other approved treatment, which has been under a global shortage for several years.

Patients with basal cell or cutaneous squamous cell carcinoma tend to have good outcomes when the disease is caught early. For those in later stages, new treatments bring hope and better prognoses.

According to an expert from The University of Texas MD Anderson Cancer Center, patient enrollment in clinical trials that involve genomic testing are important in progressing research in their cancer types.

A cancer survivor recalls the scary moment she experienced what she thought was a new life-threatening side effect.

Recent research found that women with a history of pregnancy – even if it was not carried to term – had a decreased risk of ovarian cancer.

Patients who tested positive for the biomarker circulating tumor DNA (ctDNA) had improved disease-free and overall survival after receiving Tecentriq.

Research found discrepancies between treatment recommended by clinical trial results and treatment that is typically given to patients with mantle cell lymphoma.

We may never know what triggered the global pandemic that has claimed more than 3.8 million lives. And we won’t know the long-term effects until enough time has elapsed. What we do know for certain is that the incredible strength and collaboration of the scientific community have allowed us to regain some semblance of normalcy.

Remember when you were a child and your parents said to eat your vegetables to grow up strong and healthy? Well, it’s still true.

Dave Fleischer’s 15,000-mile journey turned out to be more impactful than he anticipated. He traveled nationwide to spread awareness about cholangiocarcinoma, genetic testing and getting second opinions.

In patients with advanced gastrointestinal stromal tumors, a dose escalation of Qinlock after recommended treatment with the agent may be the best next step, answering for the lack of a next approved agent after Qinlock.

Patients with cancer who are treated with checkpoint inhibitors or immunotherapy, along with other treatments, run the risk of developing ILD as a side effect.

The combination of Lenvima and Keytruda was associated with improvements in survival and response rates over Sutent alone in various subgroups of patients with advanced renal cell carcinoma.

Many women with breast cancer choose to undergo reconstruction after mastectomy. Of those women, some opt for nipple sparing surgeries while others do not. “Those who choose to save their nipples are often disappointed when the tissue dies or no longer functions as it did before surgery,” writes one survivor. “But why are nipples so important?”

Opdivo was the first PD-1 inhibitor to show durable responses in patients with esophageal squamous cell carcinoma.